Opinion

Video

Shared Decision-Making for IgAN Treatment

Key Takeaways

  • Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
  • Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
SHOW MORE

Panelists discuss how shared decision-making is essential when considering emerging treatments vs established therapies, emphasizing the importance of aligning treatment choices with patient preferences and values to enhance adherence and optimize outcomes in IgA nephropathy care.

  1. What role does shared decision-making play when considering emerging treatments vs established therapies?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
Advocating for Race-Neutral Approach to Pulmonary Function Testing with Meredith McCormack, MD, and Loretta Que, MD
Gregory Mattingly, MD I St. Charles Psychiatric Associates
© 2025 MJH Life Sciences

All rights reserved.